A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies

Inclusion Criteria

• •1\. Subjects voluntarily participated and signed a written informed consent form
• •Age ≥ 18 years, male or female
• •ECOG performance status of 0-2
• •Expected life-expectancy ≥ 3 months
• •CD70+ relapsed/refractory hematologic malignancies
• •Adequate organ function prior to QLS2309 administration
• •Female patients with fertility must agree to the use of effective contraceptive methods during the study period and within 35 days of discontinuation of the trial drug.
• •Male patients whose sexual partners are women of childbearing age must agree to use condoms during the study period and within 35 days of discontinuation of the trial drug during sexual intercourse.